ASSESSMENT OF INDUCED SPUTUM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 为了确定用高渗盐水诱导的痰中中性粒细胞、活性弹力酶和细胞因子是否是有用的筛查试验，以确定具有已知抗炎特性的特定药物是否适合进行更广泛的临床试验。这一目标将通过一种抗炎药布洛芬和一种抗炎药塞来昔布来实现，布洛芬已被证明对CF具有临床益处，塞来昔布可能对CF具有临床益处。另设“不接受治疗”的手臂作为对照组。对于临床稳定的CF患者，将在治疗前(基准期)、治疗期(治疗期)和恢复期(恢复期)之前(基准期)和之后(恢复期)对诱导痰标本的结果进行评估。变化将在每个手臂内和手臂之间进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine whether neutrophils, active elastase, and cytokines measured in sputum induced using hypertonic saline are useful screening tests for determining if a particular agent with known anti-inflammatory properties is a suitable candidate for more extensive clinical trials in patients with CF. This aim will be addressed using one anti-inflammatory agent, ibuprofen, that has been shown to have clinical benefit in CF, and one anti-inflammatory agent, celecoxib, that has potential to have clinical benefit in CF. A "no treatment" arm will be included as the control group. The outcome measures will be assessed in induced sputum specimens before (Baseline Period), during (Treatment Period), and after (recovery Period) a 4-week treatment period in clinically stable CF patients. Changes will be assessed within each arm and between arms.